Major 2025 Update: FDA Removes Long-standing “Black Box” Warnings from Menopausal Hormone Therapy
On November 10, 2025, the U.S. Department of Health and Human Services (HHS) and FDA announced a historic shift: they initiated the removal of the class-wide “black box” warnings on most hormone therapy products for menopause (MHT).
The warning — in place since 2003 — had highlighted elevated risks for cardiovascular disease, breast cancer, and probable dementia, based largely on early findings from the Women’s Health Initiative (WHI). After a comprehensive re-review of decades of research, updated drug-use data, a public comment period, and a July 2025 expert panel, the FDA determined those warnings no longer reflect current evidence for many modern hormone therapies — especially when initiated around menopause onset rather than in older age. As a result, product labeling will change. While detailed risks will remain in package inserts, the strongest “fear-driven” labeling is being removed.
What This Means for You
Hormone therapy (estrogen alone or estrogen–progestogen) remains FDA-approved to relieve menopausal symptoms like hot flashes, night sweats, and genitourinary changes — and in some cases to help prevent bone loss.
For many women — especially those under 60 or within 10 years of menopause onset — data now suggest MHT may carry lower risks than once feared. When started early after menopause, MHT has been associated with reductions in all-cause mortality, bone fractures, and possibly lowered risks of heart disease and cognitive decline.
The decision to use MHT should be individualized. This update restores the possibility for informed, nuanced conversations — not blanket fear — so that people can weigh benefits and risks with their providers.
Updated Guidance & Practical Takeaways:
If you’ve previously avoided hormone therapy because of “black-box warning” fear — know that the landscape has changed. This is a new moment for conversation and reconsideration.
- The timing of therapy matters: starting MHT within 10 years of menopause onset or before age 60 is emphasized as an important factor in maximizing benefits and minimizing risk.
- Options vary widely — pills, patches, topical gels, low-dose vaginal estrogen — with different risk/benefit profiles. What’s right for you depends on your health history, symptoms, and comfort level.
- Even though the black-box warning is being removed, it’s still critical to talk with your clinician about your personal and family history, as MHT may not be appropriate for everyone — particularly for systemic estrogen-only therapy in people with a uterus (where endometrial cancer risk remains).
Why This Matters for Women of Color
For many Black and other women of color, menopause care has long been shaped by fear, confusion, and mis- or under-information. The FDA’s decision represents an opportunity to reclaim agency and normalize honest, individualized menopause conversations. With safer, better-labeled options, more women can consider whether MHT fits their needs — potentially removing barriers to relief from disruptive symptoms that disproportionately affect quality of life and mental health during midlife.
UPDATED DECEMBER 2025